Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD

  • Molander P
  • Sipponen T
  • Kemppainen H
 et al. 
  • 59

    Readers

    Mendeley users who have this article in their library.
  • 44

    Citations

    Citations of this article.

Abstract

Background and aims: Deep remission, meaning clinical remission with mucosal healing (MH), with anti-tumor necrosis factor-alpha (TNF-α) agents is a new target for therapy in inflammatory bowel disease (IBD). Our aim was to study how often patients on TNF-α blocking therapy actually achieve deep remission. Methods: The total of 252 IBD patients retrospectively included (183 Crohn's disease (CD), 62 ulcerative colitis (CU) or 7 inflammatory bowel disease unclassified-type colitis (IBDU)) received TNFα-antagonists (177 infliximab, 75 adalimumab) for at least 11. months and underwent ileocolonoscopy. We reviewed endoscopic and histological findings, clinical symptoms, C-reactive protein (CRP), and fecal calprotectin (FC) levels, and data on TNF-α blocking therapy. Defining deep remission as no clinical symptoms with endoscopic remission (the simple endoscopic score for Crohn's disease, SES-CD 0-2 or Mayo endoscopic subscore 0-1). Results: Of the 252 patients, 168 (67%) were in clinical remission and 122 (48%) in deep remission after a median of 23. months of maintenance therapy. Of the 183 CD patients, 117 (64%) reached clinical remission and 79 (43%) deep remission. Of the UC patients, 52 (75%) were in clinical remission and 43 (62%) in deep remission. The majority of patients in deep remission (n = 99, 81%) also had histologically inactive disease. Both median CRP and FC levels were significantly lower in patients with deep remission. Conclusion: Reassuringly, half of the IBD patients on the TNFα-blocking maintenance therapy achieved deep remission. The majority of patients in deep remission also achieved histological remission. © 2012 European Crohn's and Colitis Organisation.

Author-supplied keywords

  • Adalimumab
  • Crohn's disease
  • IBD
  • Infliximab
  • Mucosal healing
  • Ulcerative colitis

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free